Literature DB >> 11442349

Tissue transglutaminase selectively modifies proteins associated with truncated mutant huntingtin in intact cells.

W Chun1, M Lesort, J Tucholski, P W Faber, M E MacDonald, C A Ross, G V Johnson.   

Abstract

The cause of Huntington's disease (HD) is a pathological expansion of the polyglutamine domain within the N-terminal region of huntingtin. Neuronal intranuclear inclusions and cytoplasmic aggregates composed of the mutant huntingtin within certain neuronal populations are a characteristic hallmark of HD. However, how the expanded polyglutamine repeats of mutant huntingtin cause HD is not known. Because in vitro expanded polyglutamine repeats are excellent glutaminyl-donor substrates of tissue transglutaminase (tTG), it has been hypothesized that tTG may contribute to the formation of these aggregates in HD. However, an association between huntingtin and tTG or modification of huntingtin by tTG has not been demonstrated in cells. To examine the interactions between tTG and huntingtin human neuroblastoma SH-SY5Y cells were stably transfected with full-length huntingtin containing 23 (FL-Q23) (wild type) or 82 (FL-Q82) (mutant) glutamine repeats or a truncated N-terminal huntingtin construct containing 23 (Q23) (wild type) or 62 (Q62) (mutant) glutamine repeats. Aggregates were rarely observed in the cells expressing full-length mutant huntingtin, and no specific colocalization of full-length huntingtin and tTG was observed. In contrast, in cells expressing truncated mutant huntingtin (Q62) there were numerous complexes of truncated mutant huntingtin and many of these complexes co-localized with tTG. However, the complexes were not insoluble structures. Further, truncated huntingtin coimmunoprecipitated with tTG, and this association increased when tTG was activated. Activation of tTG did not result in the modification of either truncated or full-length huntingtin, however proteins that were associated with truncated mutant huntingtin were selectively modified by tTG. This study is the first to demonstrate that tTG specifically interacts with a truncated form of huntingtin, and that activated tTG selectively modifies mutant huntingtin-associated proteins. These data suggest that proteolysis of full-length mutant huntingtin likely precedes its interaction with tTG and this process may facilitate the modification of huntingtin-associated proteins and thus contribute to the etiology of HD. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11442349     DOI: 10.1006/nbdi.2001.0390

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  9 in total

1.  Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia.

Authors:  Cristy Tower; Lianwu Fu; Rachel Gill; Mark Prichard; Mathieu Lesort; Elizabeth Sztul
Journal:  Neurobiol Dis       Date:  2010-08-20       Impact factor: 5.996

2.  Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease.

Authors:  Michael E Prime; Frederick A Brookfield; Stephen M Courtney; Simon Gaines; Richard W Marston; Osamu Ichihara; Marie Li; Darshan Vaidya; Helen Williams; Anna Pedret-Dunn; Laura Reed; Sabine Schaertl; Leticia Toledo-Sherman; Maria Beconi; Douglas Macdonald; Ignacio Muñoz-Sanjuan; Celia Dominguez; John Wityak
Journal:  ACS Med Chem Lett       Date:  2012-08-09       Impact factor: 4.345

3.  SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease.

Authors:  John Wityak; Michael E Prime; Frederick A Brookfield; Stephen M Courtney; Sayeh Erfan; Siw Johnsen; Peter D Johnson; Marie Li; Richard W Marston; Laura Reed; Darshan Vaidya; Sabine Schaertl; Anna Pedret-Dunn; Maria Beconi; Douglas Macdonald; Ignacio Muñoz-Sanjuan; Celia Dominguez
Journal:  ACS Med Chem Lett       Date:  2012-10-04       Impact factor: 4.345

4.  Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.

Authors:  Maria Borrell-Pagès; Josep M Canals; Fabrice P Cordelières; J Alex Parker; José R Pineda; Ghislaine Grange; Elzbieta A Bryson; Martine Guillermier; Etienne Hirsch; Philippe Hantraye; Michael E Cheetham; Christian Néri; Jordi Alberch; Emmanuel Brouillet; Frédéric Saudou; Sandrine Humbert
Journal:  J Clin Invest       Date:  2006-04-06       Impact factor: 14.808

5.  Oligomeric and polymeric aggregates formed by proteins containing expanded polyglutamine.

Authors:  S Iuchi; G Hoffner; P Verbeke; P Djian; H Green
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-18       Impact factor: 11.205

6.  Cross-linking of cellular proteins by tissue transglutaminase during necrotic cell death: a mechanism for maintaining tissue integrity.

Authors:  Ben Nicholas; Peter Smethurst; Elisabetta Verderio; Richard Jones; Martin Griffin
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

7.  Therapeutic Strategies in Huntington's Disease.

Authors:  Ichiro Kanazawa
Journal:  J Clin Neurol       Date:  2006-12-20       Impact factor: 3.077

8.  Mutant Huntingtin Protein Interaction Map Implicates Dysregulation of Multiple Cellular Pathways in Neurodegeneration of Huntington's Disease.

Authors:  Sonia Podvin; Sara Brin Rosenthal; William Poon; Enlin Wei; Kathleen M Fisch; Vivian Hook
Journal:  J Huntingtons Dis       Date:  2022

9.  Preventing Ataxin-3 protein cleavage mitigates degeneration in a Drosophila model of SCA3.

Authors:  Joonil Jung; Kexiang Xu; Derek Lessing; Nancy M Bonini
Journal:  Hum Mol Genet       Date:  2009-09-25       Impact factor: 6.150

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.